ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfenex And Hospira Join On Biosimilars

by Ann M. Thayer
February 16, 2015 | APPEARED IN VOLUME 93, ISSUE 7

Pfenex, a San Diego-based biotech firm, will work with the generic drug firm Hospira to develop a biosimilar version of Genentech’s eye drug Lucentis. In 2014, sales of Lucentis were about $4 billion. Hospira will pay Pfenex $51 million up front and up to $291 million more in milestone payments. Pfenex’s PF582 monoclonal antibody is in clinical trials to assess its safety and tolerability, and to compare its pharmacokinetics and pharmacodynamics to Lucentis. Pfizer is in the process of acquiring Hospira in a $17 billion deal.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment